The clinical reality of guidelines for primary prevention of cardiovascular disease in type 2 diabetes in Italy

Atherosclerosis

Volumn 198, Issue 2, 2008, Pages 396-402

  Vaccaro, O ^a   Boemi, M ^b   Cavalot, F ^c   De Feo, P ^d   Miccoli, R ^e   Patti, L ^a   Rivellese, A A ^a   Trovati, M ^c   Ardigo D ^f   Zavaroni, I ^f  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b INRCA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f UNIVERSITY OF PARMA   (Italy)

Author keywords

Cardiovascular prevention; Clinical practice; Guidelines; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DISEASE DURATION; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; RISK FACTOR; SEX DIFFERENCE; SMOKING; STANDARD;

AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; ITALY; MALE; MEDICAL AUDIT; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREVALENCE;

EID: 44149122469     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.10.026     Document Type: Article

References (27)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
2. Stratton I.M., Adler A.I., Neil H.A., Mattews D.R., Manley S.E., Cull C.A., et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 32 (2000) 405-412
3. Gaede P., Vedel O., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-386
4. The Diabetes Control and Complications Trials/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
5. Vijan S., and Hayward R.A. Pharmacologic lipid lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 140 (2004) 650-658
6. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 10 1 (2003) S1-S78
7. Comaschi M., Medea G., Panico S., et al. Linee guida per la prevenzione cardiovascolare nel paziente diabetico. Ital Heart J 3 (2002) 669-676
8. Buse J.B., Ginsber H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. A scientific statement from the American Heart Association and the American Diabetes. Assoc Circ 115 (2007) 114-126
9. Rydèn L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Guideline on diabetes, prediabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC), and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28 (2007) 88-136
10. Rose G.A., Blackburn H., Gillum R.F., and Prineas R.J. Cardiovascular survey methods. 2nd ed. (1982), WHO, Geneva [Monogr. Ser. No. 56]
11. Stevens R., Kothari V., Adler A.I., Stratton I.M., and Holman R.R. The UKPDS risk engine: a model for the risk of coronary heart disease in Type 2 diabetes (UKPDS 56). Clin Sci 101 (2001) 671-679
12. Goff D.G., Bertoni A.G., Kramer H., et al. Dyslipidemia prevalence, treatment and control in the Multi-Ethnic Study of Atherosclerosis (MESA). Gender, ethnicity, and coronary artery calcium. Circulation 13 (2006) 647-656
13. Mosca L., Mochari H., Christian A., et al. National study of women's awareness, preventive action and barriers to cardiovascular health. Circulation 113 (2006) 525-534
14. Giorda C., Maggini M., Spila Alegnani S., Turco S., Raschetti R., and DAI Study Group. Secondary prevention of coronary artery disease in high-risk diabetic patients. Nutr Met Cardiovasc Dis 13 (2003) 238-243
15. Avogaro A., Guida P., Giorda C., Mannucci E., Medea G., Comaschi M.J., et al., Progetto DIARIO (Diabetic Register in Italian Offices). The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. Nutr Met Cardiovasc Dis 17 (2007) 32-40
16. Bruno A., Grassi G., Dani F., et al. Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital. Nutr Met Cardiovasc Dis 15 (2005) 42-46
17. Stamler J., Vaccaro O., Neaton J.D., Wentworth D., and The Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
18. Vaccaro O., Eberly L.E., Neaton J.D., et al. Impact of diabetes and previous myocardial infarction on long-term survival-25 year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Int Med 164 (2004) 1438-1443
19. Euroaspire I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 357 (2001) 995-1001
20. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
21. Hartz I., Njølstad I., and Eggen A.E. Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? the Tromsø study 2001. Eur Heart J 26 (2005) 2673-2680
22. Franciosi M., Pellegrini F., De Berardis G., et al. Impact of physicians' beliefs and practices on cholesterol levels in patients with type 2 diabetes: a longitudinal assessment. Am Heart J 149 (2005) 104-111
23. Abraha I., Montedori A., Stracci F., Rossi M., and Romagnoli C. Statin compliance in Umbrian population. Eur J Clin Pharmacol 59 (2003) 659-661
24. Egede L.E., and Zheng D. Modifiable cardiovascular risk factors in adults with diabetes; prevalence and missed opportunities for physician counseling. Arch Int Med 162 (2002) 427-433
25. Vaccaro O., Imperatore G., Ferrara A., Palombino R., and Riccardi G. General practitioners' management of non-insulin dependent diabetes mellitus: does it comply with recommended standards?. Diab Nutr Metab 7 (1994) 123-129
26. Bruno G., Cavallo-Perin P., Bargero B., et al. Cardiovascular risk profile of type 2 diabetic patients cared for by general practitioners or at a diabetes clinic: a population-based study. J Clin Epidemiol 52 (1999) 413-417
27. Verlato G., Muggeo M., Bonora E., et al. Attending the diabetic center is associated with increased 5 year survival probability of diabetic patients. Diabetes Care 19 (1996) 211-215